ArticleJapanese journal of cancer research : Gann1997
Overexpression of cyclin-dependent kinase-activating CDC25B phosphatase in human gastric carcinomas.
Article in Japanese journal of cancer research : Gann, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 83 citations in OpenAlex.
- The BET inhibitor sensitivity is associated with the expression level of CDC25B in pancreatic cancer models.Cancer drug resistance (Alhambra, Calif.) · 2024Article
- In Silico Identification of Small Molecules as New Cdc25 Inhibitors through the Correlation between Chemosensitivity and Protein Expression Pattern.International journal of molecular sciences · 2021Article
- mRBioM: An Algorithm for the Identification of Potential mRNA Biomarkers From Complete Transcriptomic Profiles of Gastric Adenocarcinoma.Frontiers in genetics · 2021Article
- Natural Compounds as Modulators of Cell Cycle Arrest: Application for Anticancer Chemotherapies.Current genomics · 2017Review
- Article
- Network pharmacology dissection of multiscale mechanisms of herbal medicines in stage IV gastric adenocarcinoma treatment.Medicine · 2016Article
- Phosphatases and kinases regulating CDC25 activity in the cell cycle: clinical implications of CDC25 overexpression and potential treatment strategies.Molecular and cellular biochemistry · 2016Review
- Clinical implication of 14-3-3 epsilon expression in gastric cancer.World journal of gastroenterology · 2012Article
- Article
- CDC 25A gene 263C/T, -350C/T, and -51C/G polymorphisms in breast carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2010Article
- Article
- Inappropriate activation of cyclin-dependent kinases by the phosphatase Cdc25b results in premature mitotic entry and triggers a p53-dependent checkpoint.The Journal of biological chemistry · 2009Article
- Small interfering RNA targeting CDC25B inhibits liver tumor growth in vitro and in vivo.Molecular cancer · 2008Article
- The anti-tumour agent, cisplatin, and its clinically ineffective isomer, transplatin, produce unique gene expression profiles in human cells.Cancer informatics · 2008Article
- A novel cinnamic acid derivative that inhibits Cdc25 dual-specificity phosphatase activity.Cancer science · 2005Article
- Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma.Oncogene · 2004Article
- Dual-specificity phosphatases as targets for antineoplastic agents.Nature reviews. Drug discovery · 2002Review
- Expression of cdc25A and cdc25B proteins in thyroid neoplasms.British journal of cancer · 2002Article
- Cdc25B functions as a novel coactivator for the steroid receptors.Molecular and cellular biology · 2001Article
- Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus.British journal of cancer · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CDC25 phosphatases activate cyclin-dependent kinases by removing inhibitory phosphate groups on the molecules and positively regulate the cell cycle progression. The expression of CDC25A, B and C was examined in gastric carcinoma cell lines and gastric carcinoma tissues by northern blotting and immunohistochemistry. The gastric carcinoma cell lines expressed CDC25A, B and C mRNA at various levels. The expression levels of CDC25B were generally higher than those of CDC25A and C. Of the 40 gastric carcinomas, 70% of the tumors expressed CDC25B mRNA at higher levels than the corresponding normal mucosas, while 38% overexpressed CDC25A mRNA. The CDC25C expression was at very low or undetectable levels. No obvious correlation was detected between the expression of CDC25B and p53 gene mutations. Immunohistochemically, CDC25-positive tumor cells were detected in 43 (78%) of 55 gastric carcinoma cases, of which 27 (49%) were strongly positive. Strong expression of CDC25B protein was associated with advanced stage and deep invasion. Furthermore, the incidence of strong expression was significantly higher in carcinomas with nodal metastasis than in those without metastasis. These findings suggest that overexpression of CDC25B may favor development and progression and may be an indicator of malignant behavior of gastric carcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.